CO-MORBIDITIES AMONG EPILEPSY PATIENTS: EXPERIENCE IN BANGLADESH

RAJIB NAYAN CHOWDHURY¹, ATM HASIBUL HASAN², KAZI MOHIBUR RAHMAN³, SUDIP RANJAN DEB⁴

Abstract:
Objective: To determine comprehensively all the major comorbid diseases observed among epilepsy patients.
Methods: In this observational study, 1168 patients were recruited from outpatient based epilepsy clinic in a tertiary care hospital. Four categories of comorbid conditions namely neuropsychiatric, developmental (mental retardation, cerebral palsy), pain disorder (migraine) and others (hypertension, diabetes, stroke) were evaluated in these patients through a prefilled questionnaire and data were then analyzed. Epilepsy were broadly classified into generalized epilepsy (GE), localization related epilepsy (LRE), symptomatic and unclassified.
Result: Among the 1168 subjects we included in this study, 71.5% were male. The most common age group at the time of interview was 11-20 years (36.8%). Only 29 (2.5%) respondents were older than 60 years. Among the listed comorbid conditions, mental retardation was the most common entity (15.5%), followed by psychiatric disorder (12.8%), hypertension (5.6%), migraine (5.4%) and cerebral palsy (5.0%). Only 1.5% had diabetes and 0.6% had stroke. Mental retardation and cerebral palsy were more common and significantly associated (p=0.0001 and 0.005) with GE patients (95 and 44), psychiatric disorder was also common among GE patients (108) with a p value of 0.0001. But migraine was more common and significantly associated (p=0.0001) with LRE patients (46). Stroke was only present in symptomatic epilepsy group (7) and diabetes was present only in GE patients (19). Both were significant (p= 0.0001 and 0.01). But hypertension among different epilepsy groups was not significant (p= 0.08).
Conclusion: Neuropsychiatric, developmental and pain disorder are common comorbid associations within different epilepsy syndromes which may need special care during management of epilepsy patients.
Key Words: Comorbidity, Hypertension (HTN), Diabetes Mellitus (DM)

Introduction:
An estimated 59 million people is affected by epilepsy worldwide¹. The prevalence of active epilepsy, range from 0.2- 4.1%². Although defined by presence of recurrent seizure, epilepsy has different dimensions including abnormality in cognition, psychiatric status, social adaptation and many more. In the past centuries people with epilepsy were frequently segregated in colonies³. Epileptologists subsequently sought to provide a more representative picture of the consequences of epilepsy in people who lived in the community⁴. The term “comorbidity” refers to one or more other disease among people with an index disease⁵. It is often difficult to determine whether a clinical entity should be marked as comorbidity or complication of the disease itself. The working definition of complication is regarded as existence of a second disease when the occurrence of an index disease is required⁶. Few years back, at the National Institutes of Health conference Curing Epilepsy 2007: Translating Discoveries into Therapies, the prevention and reversal of the comorbidities of epilepsy were identified as a major new benchmark area for research. A number of conditions have been reported to be comorbid with epilepsy, including psychiatric disorders and certain pain disorders, the improved knowledge base of which is very much important. Firstly, the awareness of comorbidities can improve diagnosis. Secondly, some comorbidities may influence the prognosis of epilepsy, as has been shown for migraine⁷. Thirdly, the recognition of comorbidities can inform therapeutic choices. It can either create opportunities to treat two conditions with a single drug or impose therapeutic limitations. Thus the knowledge of comorbidities may provide insight into pathogenesis by revealing shared neurobiologic

1. Assistant Professor of Neurology, Dhaka Medical College Hospital
2. Medical Officer, OPD (Medicine), Dhaka Medical College Hospital
3. Assistant Professor of Neurology, Dhaka Medical College Hospital
4. Resident Physician, Dhaka Medical College Hospital

Bangladesh J Medicine 2013; 24 : 65-69
mechanisms underlying multiple disorders. In this study we tried to find out the distribution of different comorbid condition in different types of epilepsy patients. The list of comorbidities were selected on the basis of prior research8-10.

Materials and Methods:
This cross sectional study was carried out in specialized epilepsy weekly outpatient clinic of Dhaka medical college from January 2008 to July 2011 which included 1168 epilepsy patients. Epilepsy syndromes were broadly classified into four categories using the classification system of International League Against Epilepsy (ILAE) namely, generalized epilepsy (GE), localization related epilepsy (LRE), symptomatic and unclassified. Each patient was evaluated and classified by consultant neurologist. Four categories of comorbid conditions namely neuropsychiatric, developmental (mental retardation, cerebral palsy), pain disorder (migraine) and others (hypertension, diabetes, stroke) were evaluated in these patients through a prefilled questionnaire. These comorbidities were selected on the basis of our knowledge base from prior researches. Statistical analysis of their response was done with the help of SPSS version 16.0.

Result:
Among the 1168 subjects we included in this study, 71.5% were male. The most common age group at the time of interview was 11-20 years (36.8%), followed by 27.7% young adults who were at 21-30 years of age (Table-I). Only 29 (2.5%) respondents were older than 60 years. Among the listed comorbid conditions, mental retardation was the most common entity (15.5%), followed by psychiatric disorder (12.8%), hypertension (5.6%), migraine (5.4%) and cerebral palsy (5.0%). Only 1.5% had diabetes and 0.6% had stroke (Figure-I). Further subgroup analysis of developmental disorder showed that mental retardation and cerebral palsy were more common and significantly associated (p=0.0001 and 0.005) with GE patients (95 and 44) than LRE (75 and 17) respectively (Table-II). Similarly psychiatric disorder was also common among GE patients (108) than LRE (50) with a p value of 0.0001. But migraine was more common and significantly associated (p=0.0001) with LRE patients (46) than GE (20) (Table-II). Stroke was only present in symptomatic epilepsy group (7) and diabetes was present only in GE patients (19). Both were significant with p value of 0.0001 and 0.01 respectively. Though hypertension was common, the difference for hypertension among different epilepsy groups was not significant (p=0.08).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-10 yrs</td>
<td>217</td>
<td>18.6</td>
</tr>
<tr>
<td>11-20 yrs</td>
<td>430</td>
<td>36.8</td>
</tr>
<tr>
<td>21-30 yrs</td>
<td>323</td>
<td>27.7</td>
</tr>
<tr>
<td>31-40 yrs</td>
<td>109</td>
<td>9.3</td>
</tr>
<tr>
<td>41-50 yrs</td>
<td>31</td>
<td>2.7</td>
</tr>
<tr>
<td>&gt;60 yrs</td>
<td>29</td>
<td>2.5</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>835</td>
<td>71.5</td>
</tr>
<tr>
<td>Female</td>
<td>333</td>
<td>28.5</td>
</tr>
</tbody>
</table>

Table II

<table>
<thead>
<tr>
<th>Parameter</th>
<th>GE</th>
<th>LRE</th>
<th>Symptomatic</th>
<th>Unclassified</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental retardation</td>
<td>95</td>
<td>75</td>
<td>14</td>
<td>7</td>
<td>0.0001</td>
</tr>
<tr>
<td>Cerebral Palsy</td>
<td>44</td>
<td>17</td>
<td>0</td>
<td>0</td>
<td>0.005</td>
</tr>
<tr>
<td>Psychiatric disorder</td>
<td>108</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>0.0001</td>
</tr>
<tr>
<td>Migraine</td>
<td>20</td>
<td>46</td>
<td>0</td>
<td>0</td>
<td>0.0001</td>
</tr>
<tr>
<td>Stroke</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>0.0001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>46</td>
<td>16</td>
<td>7</td>
<td>0</td>
<td>0.08</td>
</tr>
<tr>
<td>Diabetes</td>
<td>19</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.01</td>
</tr>
</tbody>
</table>
Discussion:
Researchers have reported that 4% to 10% of all children experience a seizure at some time in their lives. By age 20, however, only 1% of the population has a diagnosis of seizures or epilepsy. Many patients with developmental disorders present with an epilepsy comorbidity. For example, seizures appear in more than 20% of children with cerebral palsy, unspecified cognitive impairment, pervasive developmental delay, as well as in specific genetic syndromes associated with cognitive impairment. In addition, there are different types of epilepsy that may be associated with different types of developmental disability. Both the paper electroencephalogram (EEG) and the video EEG remain the most valuable tools that are used to evaluate patients with both epilepsy and a developmental disorder. Investigators have studied the co-morbidity of epilepsy and numerous childhood onset conditions, including cerebral palsy, autism, Down syndrome, and mental retardation. The clinical response to anticonvulsant is neuroanatomical abnormalities or metabolic disorders. The distribution of various subtypes of the spectrum of mental retardation, the frequency of onset conditions, including cerebral palsy, autism, Down syndrome, and mental retardation.

Recent reports about children with cerebral palsy indicate that 35% have a history of epilepsy, with the highest prevalence in children with spastic hemiplegia (66%), followed by those with quadriplegia (43%), and diplegia (16%). Similar to the reports from other investigators, mental retardation and cerebral palsy were significantly associated with GE patients (p value 0.0001 and 0.005 respectively) in our study. The relationship between seizure disorders and mental retardation is a complex one. When considered across the spectrum of mental retardation, the frequency and severity of epilepsy varies inversely with the level of mental retardation. Among individuals with mild retardation, the distribution of various subtypes of seizures approximates the general population. This observation probably relates to lower rates of neuroanatomical abnormalities or metabolic disorders. The clinical response to anticonvulsant is also comparable to the general population. Among individuals with severe/profound retardation, increased rates of underlying neurological abnormalities are manifested by a higher frequency of mixed seizure disorders, and an onset of seizures in infancy or early childhood. This factor contributes to higher rates of uncontrollable seizures and neuropsychiatric complications. These clients may also require multiple anticonvulsants (AEDs), increasing the risk for medication side effects and pharmacokinetics interactions. Even with AED combinations, many clients continue to experience frequent seizures and risk further cognitive or behavioral deterioration. The degree of clinical deterioration relates to frequent seizures; early age of onset, level of seizure control with the time required, and the presence of underlying neuroanatomical lesions. There is also a considerable overlap between mental retardation and other developmental disorders with psychiatric diseases. Population studies indicate that rates of psychiatric disorders approach 40% of the population of individuals with mental retardation. The categories of psychopathology vary depending on the level of mental retardation and deficits in adaptive behavior, and genetic vulnerability to disorders such as affective illness, anxiety disorders, and schizophrenia.

In our study for the purpose of simplification, we grouped disorders like depression, anxiety, panic attacks, schizophrenia all together under the heading psychiatric disorder. About 12.8% of our patients had at least one variety of this psychiatric diagnosis along with epilepsy. The significant association was with GE patients (p=0.0001) Psychiatric disorders have been a longstanding concern in tertiary care epilepsy centres. Recent population-based studies that use contemporary diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) and the International Classification of Diseases, are crucial to define the extent of the problem. Tellez-Zenteno and co-workers investigated mental health status in 36,984 people who participated in the Canadian Community Health Survey 1.2. The World Mental Health Composite International Diagnostic Interview was used to derive 12-month and lifetime rates of DSM-IV axis I disorders. Patients with epilepsy were more likely to report lifetime anxiety disorders and suicidal thoughts, and lifetime major depression was significantly higher after adjustment for covariates. Population-based investigations of the associations between epilepsy and psychiatric disorders compared with other chronic health conditions are important. Recent studies of targeted psychiatric symptoms in large, community-based populations investigate this question. For example, Ettinger and co-workers studied symptoms of depression and bipolar disorder with self report inventories. Bipolar symptoms were significantly elevated in patients with epilepsy (12.2%) compared with patients with migraine (7.2%), asthma (5.9%), diabetes (3.2%), or controls (1.7%). Many studies have consistently shown an increased risk of depression after epilepsy onset, some data also shows that the depressed individuals have increased risk of developing epilepsy. This bidirectional relationship supports the hypothesis of overlapping mechanisms for the two disorders. Whether the population based prevalence rates of psychiatric
disorders are increased in patients with epilepsy compared with people with other neurological disorders (eg, multiple sclerosis) needs to be determined and is a crucial question with regard to the specificity of association. Findings also suggest that psychiatric, cognitive and behavioral problems might even antedate the diagnosis of epilepsy33,34.

Migraine and epilepsy are associated independent of seizure type, etiology, age at onset, or family history of epilepsy35. These two conditions might share a common genetic susceptibility36 or a common environmental risk factor, such as traumatic head injury37. Depression and migraine with aura act synergistically in increasing the risk of incident unprovoked seizure, suggesting that these three disorders may result from a shared underlying mechanism38. A recent study reported an increased frequency of migraine in the relatives of individuals with benign rolandic epilepsy, providing evidence for a shared genetic susceptibility to migraine and some forms of epilepsy36. Finding in our study was a little bit different. Migraine was strongly associated with LRE \((p=0.0001)\). There are several possible explanations for the co-occurrence of these two disorders39-41. First, since migraine and epilepsy are both relatively common, they may co-occur frequently by chance. Second, they may be mistaken for one another, as migraine and epilepsy—particularly partial seizures— have considerable overlap of clinical symptoms. Third, one may cause the other—migraine may trigger or evolve into a seizure ("migralepsy")41 and seizures may cause post-ictal headache. Fourth, they may have a shared pathophysiology, such as ion channel dysfunction, that is not necessarily the result of shared genetic factors. Finally, migraine and epilepsy may have a shared genetic cause, a topic addressed in this issue of Neurology by Deprez et al., in their description of linkage of familial occipitotemporal lobe epilepsy and migraine with visual aura to chromosome 9q12. The risk of migraine has been found to be more than twice as high in individuals with epilepsy as in those without epilepsy35.

Stroke was only associated with symptomatic epilepsy group \((p=0.00001)\). Engel43 also reported similarly that symptomatic epilepsy results from known condition such as neoplasm, vascular malformation, stroke, scar etc. High blood pressure was also reported by a good fraction of epilepsy patients. It is a risk factor for stroke, which itself is a risk factor for epilepsy, but a direct association between high blood pressure and epilepsy was not found in our study and not reported in any literature yet. But complying with the reports of other studies the association of diabetes was significant \((p=0.01)\) There is evidence to suggest that antibodies to glutamic acid decarboxylase, an auto-antigen implicated in type 1 diabetes, are also associated with the development of epilepsy44.

**Conclusion:**
The neuropsychiatric, developmental and pain disorders are quite common comorbid conditions among epilepsy patients. Similarity in pathophysiologic mechanisms might cause these overlapping conditions within same individual. Treating physicians should be attentive to the possibility of these comorbidities in patients with epilepsy. We are in dare need of future research to examine the impact of comorbidities on treatment outcomes in epilepsy.

**Conflict of interest:** None

**References:**
18. RATEY, JJ and DYNEK, MP. "Neuropsychiatric Mental Retardation and Cerebral Palsy" in FOGEL, BS and SCHIFFER, RB (Eds) Neuropsychiatry, Williams and Wilkins Baltimore. 1996; P549-70.
21. Trimble, MR; Ring HA; and Schmitz, B. "Neuropsychiatric Aspects of Epilepsy" in FOGEL MS and SCHIFFER, RB (Des) Neuropsychiatry Williams and Wilkins Baltimore 1996; p 771-804.